FDA Brief

Warning letters Drugs

FDA warning letter to

CARsgen Therapeutics Corporation

High riskIssued Jul 26, 2024Posted Aug 27, 2024Center for Biologics Evaluation and Research

FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.

What happened

FDA inspected the Durham, NC facility from November 28, 2023, to December 6, 2023, and documented significant current good manufacturing practice (CGMP) violations for two investigational CAR T cell products. FDA cited a box of food covered in scuttle fly pupae left in a mechanical room, scuttle fly larvae in ten monitoring samples and a live scuttle fly in a cleanroom, plus missing environmental monitoring and cleaning validation. CARsgen later paused manufacturing on December 12, 2023, and told clinics not to administer previously released products.

What FDA found

  1. The firm found a box of food from June 16, 2023 covered in scuttle fly pupae in a mechanical room and did not remove it until July 31, 2023; later, scuttle fly larvae were found in ten environmental and personnel monitoring samples and a live scuttle fly was seen on a tube rack in a cleanroom.

    21 CFR 211.56(a)
  2. The firm did not monitor non-viable particulates or viable microbes in air during open manufacturing in the aseptic processing area used for its products.

    21 CFR 211.42(c)(10)(iv); 21 CFR 211.113(b)
  3. The firm had not validated the cleaning process for equipment used to make its sterile products and did not provide results from a disinfectant efficacy study.

    21 CFR 211.42(c)(10)(v)
  4. The firm had no written procedure for 100% visual inspection of the final drug product to ensure it was essentially free from visible particulates.

    21 CFR 211.100(a)
  5. Personnel microbial monitoring action-limit excursions occurred, proposed corrective and preventive actions were not implemented, more excursions occurred, and products were released afterward.

    21 CFR 211.192

What FDA wants

FDA asks CARsgen to respond in writing within 15 working days with specific steps and documentation to correct the violations and prevent recurrence, or explain the delay and completion timeframe.

Who should pay attention

  • clinical trial sponsors and sites using CARsgen products
  • contract manufacturers and labs making sterile cell therapies
  • quality teams managing aseptic environmental monitoring and cleaning validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk